期刊
FRONTIERS IN MEDICINE
卷 8, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2021.644594
关键词
HLCs; primary human hepatocytes; liver disease; clinical application; IPS cell
资金
- Talent Innovation and Entrepreneurship Project of Lanzhou City [2019-RC-34]
- Science and Technology Project of ChengGuan District, Lanzhou [2020SHFZ0029]
Liver diseases are a significant global health concern, often leading to poor survival rates, prompting the need for liver transplantation as a main alternative treatment. The emerging goal of stem cell research is to investigate the molecular mechanisms underlying complex liver diseases. Human induced pluripotent stem cells (hiPSCs) offer a promising alternative approach to treating liver diseases and serve as a potential model for studying complex liver diseases.
Liver diseases are a major health concern globally, and are associated with poor survival and prognosis of patients. This creates the need for patients to accept the main alternative treatment of liver transplantation to prevent progression to end-stage liver disease. Investigation of the molecular mechanisms underpinning complex liver diseases and their pathology is an emerging goal of stem cell scope. Human induced pluripotent stem cells (hiPSCs) derived from somatic cells are a promising alternative approach to the treatment of liver disease, and a prospective model for studying complex liver diseases. Here, we review hiPSC technology of cell reprogramming and differentiation, and discuss the potential application of hiPSC-derived liver cells, such as hepatocytes and cholangiocytes, in refractory liver-disease modeling and treatment, and drug screening and toxicity testing. We also consider hiPSC safety in clinical applications, based on genomic and epigenetic alterations, tumorigenicity, and immunogenicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据